<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="viruses and that prophylaxis does not increase resistance. In fact," exact="amantadine" post="prophylaxis has been tested in a pandemic situation, and"/>
 <result pre="adamantanes, NAIs appear at least as efficacious. The 2 NAIs," exact="zanamivir" post="and oseltamivir, gave similar results when given daily for"/>
 <result pre="head-to-head studies have been carried out. Studies of treatment with" exact="amantadine" post="and rimantadine did not allow firm estimates of how"/>
 <result pre="have been carried out. Studies of treatment with amantadine and" exact="rimantadine" post="did not allow firm estimates of how much they"/>
 <result pre="are fully pathogenic and transmissible (27). While resistance occurs when" exact="oseltamivir" post="is used in treatment, it is far less frequent"/>
 <result pre="in contrast, is absorbed and metabolized. While human studies of" exact="oseltamivir" post="in treatment would be critical now, such studies have"/>
 <result pre="data are available. Mouse studies have already indicated that, while" exact="oseltamivir" post="is effective, it is not as effective when given"/>
 <result pre="systemic and case fatality is high, among the NAIs only" exact="oseltamivir" post="would be useful, since it is absorbed (39). Given"/>
 <result pre="prophylaxis in place rapidly in rings around cases. Supplies of" exact="oseltamivir" post="are also an issue. Will those countries with stockpiles"/>
 <result pre="LenevaIA, GoloubevaOG, BushK, WebsterRDComparison of efficacies of RWY-270201, zanamivir, and" exact="oseltamivir" post="against H5N1, H9N2, and other avian influenza viruses.Antimicrob Agents"/>
 <result pre="PoretzD, PaarD, et al.Use of the selective oral neuraminidase inhibitor" exact="oseltamivir" post="to prevent influenza.N Engl J Med. 1999;341:1336–4310.1056/NEJM19991028341180210536125 25. YounkinSW,"/>
 <result pre="26. DoyleWJ, SkonerDP, AlperCM, AllenG, MoodySA, SerokyJT, et al.Effect of" exact="rimantadine" post="treatment on clinical manifestations and otologic complications in adults"/>
 <result pre="HaydenFG, HayAJEmergence and transmission of influenza A viruses resistant to" exact="amantadine" post="and rimantadine.Curr Top Microbiol Immunol. 1992;176:119–3010.1007/978-3-642-77011-1_81600749 28. WhitleyRJ, HaydenFG,"/>
 <result pre="1992;176:119–3010.1007/978-3-642-77011-1_81600749 28. WhitleyRJ, HaydenFG, ReisingerKS, YoungN, DutkowskiR, IpeD, et al.Oral" exact="oseltamivir" post="treatment of influenza in children.Pediatr Infect Dis J. 2001;20:127–3310.1097/00006454-200102000-0000211224828"/>
 <result pre="Infect Dis. 2004;190:1627–3010.1086/42457215478068 31. KaiserL, KeeneON, HammondJMJ, ElliottM, HaydenFGImpact of" exact="zanamivir" post="on antibiotic use for respiratory events following acute influenza"/>
 <result pre="Med. 2000;160:3234–4010.1001/archinte.160.21.323411088083 32. KaiserL, WatC, MillsT, MahoneyP, WardP, HaydenFGImpact of" exact="oseltamivir" post="treatment on influenza-related lower respiratory tract complications and hospitalizations.Arch"/>
 <result pre="and hospitalizations.Arch Intern Med. 2003;163:1667–7210.1001/archinte.163.14.166712885681 33. MontoAS, MoultAB, SharpSJEffect of" exact="zanamivir" post="on duration and resolution of influenza symptoms.Clin Ther. 2000;22:1294–30510.1016/S0149-2918(00)83026-X11117654"/>
 <result pre="WebsterRG, GovorkovaEAVirulence may determine the necessary duration and dosage of" exact="oseltamivir" post="treatment for highly pathogenic A/Vietnam/1203/04 (H5N1) influenza virus in"/>
</results>
